The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

  • JackbyDev@programming.devEnglish
    1·
    7 months ago

    Don’t give me that ‘hindsight is 20/20’, it was the first thought I had when I heard about this.

    ‘How are they going to monetize this?’

    The tests weren’t free.